公开(公告)号：US4985569A

公开(公告)日：1991-01-15

申请号：US350990

申请日：1989-05-12

申请人： Masayasu Kurono ,  Yasuaki Kondo ,  Ryoichi Unno ,  Yukiharu Matsumoto ,  Hiromoto Kimura ,  Mitsuru Oka ,  Kiichi Sawai

发明人： Masayasu Kurono ,  Yasuaki Kondo ,  Ryoichi Unno ,  Yukiharu Matsumoto ,  Hiromoto Kimura ,  Mitsuru Oka ,  Kiichi Sawai

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： 7a-Nitromethyl-2,3,5,6,7,7a-hexahydro-1H-pyrrolizine of the formula ##STR1## and salts thereof, as well as processes for the preparation of the compound and 7a-aminomethyl-2,3,5,6,7,7a-hexahydro-1H-pyrrolizine and salts thereof.

公开(公告)号：US4952568A

公开(公告)日：1990-08-28

申请号：US348922

申请日：1989-05-08

申请人： Kiichi Sawai ,  Masayasu Kurono ,  Hiromoto Asai ,  Takahiko Mitani ,  Kazumasa Nakano ,  Naohisa Ninomiya

发明人： Kiichi Sawai ,  Masayasu Kurono ,  Hiromoto Asai ,  Takahiko Mitani ,  Kazumasa Nakano ,  Naohisa Ninomiya

IPC分类号： A23L1/30 ,  A61K31/66 ,  A61K36/00 ,  A61K36/899 ,  A61P3/08 ,  A61P3/10

CPC分类号： A61K31/66 ,  Y10S514/866

摘要： Remedies, preventives and functional diets for diabetic diseases, esp., diabetes, contain phytic acid or its salt or salts. The salt of phytic acid is a non-toxious metal salt, or a non-toxious salt with an organic base, a basic amino acid or an organic ester residue, and has a compositional form together with or separately from phytic acid.

公开(公告)号：US4939126A

公开(公告)日：1990-07-03

申请号：US217523

申请日：1988-07-11

申请人： Masayasu Kurono ,  Tsunemasa Suzuki ,  Tomoo Suzuki ,  Kiyotaka Hirooka ,  Yukiharu Matsumoto ,  Hiroshi Ozawa ,  Kiichi Sawai

发明人： Masayasu Kurono ,  Tsunemasa Suzuki ,  Tomoo Suzuki ,  Kiyotaka Hirooka ,  Yukiharu Matsumoto ,  Hiroshi Ozawa ,  Kiichi Sawai

IPC分类号： C07F7/10 ,  A61K31/695 ,  A61P25/28 ,  C07F7/08

CPC分类号： C07F7/0812

摘要： 1-Pyrrolidineacetamide derivatives of the formula ##STR1## wherein R.sub.1 is hydrogen atom or a trialkylsilyl group, R.sub.2 and R.sub.3 are hydrogen atom, respectively, when R.sub.1 is hydrogen atom, R.sub.4 is an alkyl group, R.sub.5 is a radical of ##STR2## in which R.sub.6 and R.sub.7 are an alkyl group, respectively, m and n are an integer of 1 to 3, respectively,or R.sub.4 represents together with R.sub.5 a hetero cyclic ring having nitrogen and silicon atoms or piperazine ring having a substituent of ##STR3## in which R.sub.6 and n have the meanings as referred to, and R.sub.2 and R.sub.4 as well as R.sub.3 and R.sub.5 form a hetero cyclic ring, respectively, connected with an alkylene chain, where R.sub.1 is the trialkylsilyl group, salts thereof, a process for the preparation thereof, as well as use thereof as for a medicine.

公开(公告)号：US4870062A

公开(公告)日：1989-09-26

申请号：US183575

申请日：1988-04-19

申请人： Masayasu Kurono ,  Ryoichi Unno ,  Yukiharu Matsumoto ,  Yasuaki Kondo ,  Takahiko Mitani ,  Takahito Jomori ,  Hisashi Michishita ,  Kiichi Sawai

发明人： Masayasu Kurono ,  Ryoichi Unno ,  Yukiharu Matsumoto ,  Yasuaki Kondo ,  Takahiko Mitani ,  Takahito Jomori ,  Hisashi Michishita ,  Kiichi Sawai

IPC分类号： A61K31/28 ,  A61K31/282 ,  A61K31/55 ,  A61P35/00 ,  C07F15/00

CPC分类号： C07F15/0093

摘要： A removable rating plug for a circuit breaker provides an active variable impedance in series with a reference resistor between the sensing terminals of the circuit breaker trip circuit to adjust the sensing voltage produced in response to the input current received from current monitors in the protected circuit. The active variable impedance, which is energized by the input current, includes a high gain transistor amplifier, preferably a Darlington transistor, controlled by an operational amplifier. A control circuit includes a pair of reference diodes which match the forward drop across the Darlington transistor when full on, in series with a reference voltage selection circuit which applies a reference voltage to the non-inverting input of the operational amplifier. The voltage at the connection between the Darlington transistor and the reference resistor is fed back to the inverting input of the operational amplifier so that the gain of the amplifier, and therefore the variable impedance in series with the reference resistor, varies with the reference voltage.

公开(公告)号：US4824855A

公开(公告)日：1989-04-25

申请号：US119227

申请日：1987-11-05

申请人： Masayasu Kurono ,  Tsunemasa Suzuki ,  Yasuaki Kondo ,  Kenji Hamase ,  Toshinao Usui ,  Tomoo Suzuki ,  Masato Fukushima ,  Kiichi Sawai

发明人： Masayasu Kurono ,  Tsunemasa Suzuki ,  Yasuaki Kondo ,  Kenji Hamase ,  Toshinao Usui ,  Tomoo Suzuki ,  Masato Fukushima ,  Kiichi Sawai

IPC分类号： C07D211/90 ,  A61K31/455 ,  C07D211/86

CPC分类号： C07D211/90

摘要： 1,4-Dihydropyridine derivatives represented by the formula ##STR1## wherein one of R.sup.1 and R.sup.2 is cycloalkylmethyl group and the other is a group of ##STR2## in which R.sup.3 is hydrogen atom or lower alkyl group and R.sup.4 is hydrogen atom, hydroxyl radical, carboxyl radical, alkoxycarbonyl group, carbamoyl radical, phenyl radical, substituted phenyl radical or trialkylsilyl group, or R.sup.3 and R.sup.4 may be bonded each other, and n and m are an integer of 1 to 6, respectively salts thereof, a process for the preparation of same as well as a pharmaceutical agent comprising the compound or salt, as an effective ingredient.

摘要翻译： 由式＆lt; IMAGE＆gt;表示的1,4-二氢吡啶衍生物，其中R 1和R 2中的一个是环烷基甲基，另一个是其中R 3是氢原子或低级烷基且R 4是氢原子的基团， ，羧基，烷氧基羰基，氨基甲酰基，苯基，取代的苯基或三烷基甲硅烷基，或者R 3和R 4可以彼此键合，n和m分别为1〜6的整数，其盐， 作为有效成分，可以制备相同的药剂以及包含该化合物或盐的药剂。

公开(公告)号：US5560925A

公开(公告)日：1996-10-01

申请号：US316848

申请日：1994-10-03

申请人： Kiichi Sawai ,  Takahiko Mitani ,  Naohisa Ninomiya ,  Yoshiro Ishiwata

发明人： Kiichi Sawai ,  Takahiko Mitani ,  Naohisa Ninomiya ,  Yoshiro Ishiwata

IPC分类号： C07F7/30 ,  C08G79/00 ,  A61K9/20

CPC分类号： C07F7/30 ,  C08G79/00

摘要： Wart of human being is prevented or cured by administration of a pharmaceutical composition containing an eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84.

摘要翻译： 通过给药含有具有经验式为C 6 H 10 Ge 2 O 7的2-氧基甲基丙酸的八种结构聚合物的药物组合物，（O + E，fra 1/2 + EE）3GeCH 2 CH 2 COOH的最小结构单元和 以下立体结构：其中R代表-CH2CH2COOH，m是137 +/- 84的整数。

公开(公告)号：US5730971A

公开(公告)日：1998-03-24

申请号：US361442

申请日：1994-12-20

申请人： Yoshiro Ishiwata ,  Takahito Jomori ,  Hidetsugu Saito ,  Takahiko Mitani ,  Kiichi Sawai

发明人： Yoshiro Ishiwata ,  Takahito Jomori ,  Hidetsugu Saito ,  Takahiko Mitani ,  Kiichi Sawai

IPC分类号： A61K31/525 ,  A61K31/675 ,  A61K31/70 ,  A61K35/407 ,  A61K38/21 ,  A61P31/12 ,  A61P43/00

CPC分类号： A61K31/70 ,  A61K35/407 ,  A61K38/21

摘要： A potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator are provided. The potentiator is a mixture of flavin adenine dinucleotide (FAD) and porcine liver extract.

摘要翻译： 提供了一种干扰素增强剂和含有干扰素及其增效剂的抗病毒活性增强组合物。 增效剂是黄素腺嘌呤二核苷酸（FAD）和猪肝提取物的混合物。

公开(公告)号：US4735943A

公开(公告)日：1988-04-05

申请号：US740775

申请日：1985-06-03

申请人： Masatoshi Ban ,  Yutaka Baba ,  Kiichi Sawai

发明人： Masatoshi Ban ,  Yutaka Baba ,  Kiichi Sawai

IPC分类号： C07D461/00 ,  A61K31/44

CPC分类号： C07D461/00

摘要： There is disclosed novel eburnamonine oxime, its derivatives and salts, process for the manufacture thereof and pharmaceutical agents containing the same. The compounds are represented by the following formula. ##STR1## wherein R is hydrogen, alkyl, alkoxyalkyl, or oxisilanylalkyl group or a group of ##STR2## R.sup.1 and R.sup.2 are same or different and respectively hydrogen, alkyl having 1 to 4 carbon atoms, aryl or aralkyl group, or R.sup.1 represents together with R.sup.2 and the neighboring nitrogen atom a non-substituted or substituted heterocyclic ring, and n is an integer of 2 or 3.

摘要翻译： 公开了新颖的桦木肟，其衍生物和盐，其制备方法和含有它们的药剂。 该化合物由下式表示。 其中R是氢，烷基，烷氧基烷基或氧化二苯基烷基，或者R 1和R 2的基团相同或不同，分别是氢，具有1-4个碳原子的烷基，芳基或芳烷基，或者R1代表一起 其中R2和相邻的氮原子是未取代或取代的杂环，n是2或3的整数。

公开(公告)号：US5532272A

公开(公告)日：1996-07-02

申请号：US246141

申请日：1994-05-20

申请人： Kiichi Sawai ,  Takahiko Mitani ,  Naohisa Ninomiya ,  Yoshirou Ishiwata

发明人： Kiichi Sawai ,  Takahiko Mitani ,  Naohisa Ninomiya ,  Yoshirou Ishiwata

IPC分类号： C07F7/30 ,  A61K31/28

CPC分类号： C07F7/30

摘要： A novel, eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84. A pharmaceutical composition containing the novel polymer is useful for preventing symptoms of an immune disease such as hepatitis or for curing such a disease.

摘要翻译： 具有经验式为C 6 H 10 Ge 2 O 7的2-羟基甲基丙酸的新型八元结构聚合物，（O1 / 2）3GeCH2CH2COOH的最小结构单元和以下立体结构：其中R代表-CH2CH2COOH，m是137的整数 +/- 84。 含有新型聚合物的药物组合物可用于预防免疫疾病例如肝炎或治愈这种疾病的症状。

公开(公告)号：US5621003A

公开(公告)日：1997-04-15

申请号：US515330

申请日：1995-08-15

申请人： Kiichi Sawai ,  Takahiko Mitani ,  Naohisa Ninomiya ,  Yoshiro Ishiwata

发明人： Kiichi Sawai ,  Takahiko Mitani ,  Naohisa Ninomiya ,  Yoshiro Ishiwata

IPC分类号： A61K31/28 ,  A61K31/80 ,  A61P3/08 ,  A61P3/10

CPC分类号： A61K31/80

摘要： A maillard reaction inhibitor comprising, as the principal component, an eight-structural polymer of 3-oxygermylpropionic acid represented by the following stereostructure (I): ##STR1## wherein R represents --CH.sub.2 CH.sub.2 COOH, and m is a weight average polymerization degree calculated on the basis of the weight average molecular weight of propagermanium propyl ester and is 137.+-.84 (137 on average with a standard deviation of .+-.3.sigma.); and having the following minimum constitutional unit:(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOHand the following empirical formula:C.sub.6 H.sub.10 Ge.sub.2 O.sub.7,a method for inhibiting the Maillard reaction, and a method for preventing and treating diseases caused by Maillard reaction such as diabetes and concurrent diseases thereof.

摘要翻译： 一种美拉德反应抑制剂，其包含由以下立体结构（I）表示的3-氧基甲基丙酸的8-结构聚合物作为主要组分：其中R表示-CH 2 CH 2 COOH，m表示重均聚合度 基于丙基丙基酯的重均分子量计算，为137 +/- 84（平均137个，标准偏差为+/- 3西格玛）; 并具有以下最小结构单元：（O + E，fra 1/2 + EE）3GeCH 2 CH 2 COOH和以下经验式：C 6 H 10 Ge 2 O 7，抑制美拉德反应的方法，以及预防和治疗美拉德反应引起的疾病的方法 作为糖尿病及其并发疾病。